Core Points - CytoDyn Inc. is a clinical-stage oncology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, with potential applications in multiple indications including triple-negative breast cancer and metastatic colorectal cancer [1][4] - CFO Robert E. Hoffman will present a corporate overview at the LD Micro Main Event XIX Investor Conference from October 19 to 21, 2025, in San Diego, California [1][2] - The presentation is scheduled for October 21, 2025, at 9 a.m. PDT, and Mr. Hoffman will be available for one-on-one meetings with attendees to discuss the company's development strategy and upcoming milestones [2] Company Information - CytoDyn is dedicated to improving patients' quality of life through therapeutic innovation and is committed to integrity, responsibility, and service [4] - The company is advancing leronlimab, which is implicated in cancer, infectious diseases, and autoimmune disorders, targeting a key regulator of immune function [4] - For more information, CytoDyn can be contacted via their website or through their corporate email [5][7]